Sai Parenterals Limited (SAIPARENT) — Financial Results | 26 May 2026

StockFin.ai

Try Free

Sai Parenterals reported FY26 consolidated revenue of ₹381 crores, up 31% YoY, driven by CDMO momentum and integration of Noumed. EBITDA reached ₹29 crores in Q4FY26, with PAT margin expanding to 1%. The company highlighted 93 new dossiers, long-term CDMO contracts, and expansion into Australia and New Zealand markets.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SAIPARENT ✨ Ask AI About This

About Sai Parenterals Limited (SAIPARENT)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹2,126.13 Cr

View full SAIPARENT stock details →

📡 Get AI alerts when SAIPARENT files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SAIPARENT — Free

💡 Ask AI about this filing

"How does this financial results affect Sai Parenterals Limited's outlook?" "What did Sai Parenterals Limited announce on 26 May 2026?" "Is this positive or negative for SAIPARENT?"

Ask AI Free →

📊 More SAIPARENT filings

See all SAIPARENT filings →

🔥 Also filed on 26 May 2026

PRINCEPIPE Prince Pipes And Fittings Limited Financial Results ROHLTD Royal Orchid Hotels Limited Financial Results PTC PTC India Limited Financial Results PRIVISCL Privi Speciality Chemicals Limited Announcement PROTEAN Protean eGov Technologies Limited Financial Results REDTAPE Redtape Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when SAIPARENT files new disclosures

Track SAIPARENT filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SAIPARENT — Free

Free account · 2 AI queries/day